Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Receivables (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Change in Receivables for 15 consecutive years, with -$38.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 1820.0% year-over-year to -$38.4 million, compared with a TTM value of $210.5 million through Dec 2025, up 428.89%, and an annual FY2025 reading of $210.5 million, up 428.89% over the prior year.
  • Change in Receivables was -$38.4 million for Q4 2025 at Neurocrine Biosciences, down from $132.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $132.3 million in Q3 2025 and bottomed at -$38.4 million in Q4 2025.
  • Average Change in Receivables over 4 years is $25.4 million, with a median of $17.6 million recorded in 2024.
  • Peak annual rise in Change in Receivables hit 925.58% in 2025, while the deepest fall reached 1820.0% in 2025.
  • Year by year, Change in Receivables stood at -$9.3 million in 2021, then skyrocketed by 330.11% to $21.4 million in 2023, then plummeted by 109.35% to -$2.0 million in 2024, then tumbled by 1820.0% to -$38.4 million in 2025.
  • Business Quant data shows Change in Receivables for NBIX at -$38.4 million in Q4 2025, $132.3 million in Q3 2025, and $79.7 million in Q2 2025.